For patients with type 2 diabetes, GLP-1 RAs are associated with an increased risk for GERD and its complications compared with SGLT-2 inhibitors.

Estimated risk ratio was lower with GLP-1 receptor agonists for those younger than 75 years, but was no different for those aged 75 years or older ...